Antheia Files for IPO Following First Commercial-Scale Production of Thebaine Using Synthetic Biology to Address Global Drug Shortages

In today’s globalized world, the stability of pharmaceutical supply chains is critical to public health. However, this chain faces multiple challenges, leading to occasional drug shortages.

To address this challenge, synthetic biology offers an efficient and sustainable approach to drug production by redesigning and constructing microbial genetic material. This method streamlines the manufacturing process and reduces production steps, thereby enhancing both production efficiency and product quality.

Synthetic biology technologies can also drive innovation in the active pharmaceutical ingredient (API) industry, enabling the cost-effective production of drug components that were previously difficult to synthesize or prohibitively expensive. For instance, by engineering microorganisms through synthetic biology to produce specific drug ingredients, it is possible to enhance global access to essential medicines and address drug shortages.

Antheia, a U.S. company that leverages synthetic biology to produce active pharmaceutical ingredients (APIs), serves as a representative case in addressing drug supply shortages. The company aims to transform the supply chain for essential medicines to eliminate drug shortages. Antheia’s synthetic biology manufacturing platform can reconstruct complex biosynthetic pathways in yeast cells and scale up fermentation to commercial levels. This approach enables on-demand, agile, and resilient biomanufacturing of key drug ingredients, replacing traditional synthetic methods that fail to meet the demands of modern healthcare.

Current pharmaceutical production methods often result in inequitable access to essential medicines. The World Health Organization estimates that more than 2 billion people worldwide lack access to essential medicines.

Shortages in the pharmaceutical supply chain may be caused by a variety of factors, including production disruptions, insufficient supply of active pharmaceutical ingredients (APIs), sharp fluctuations in market demand, pricing issues, changes in policies and regulations, as well as unpredictable factors such as natural disasters and geopolitical events.

Shortages of active pharmaceutical ingredients (APIs), often driven by unstable raw material supplies, rising prices, and environmental and safety concerns during production, are a primary cause of finished drug shortages. Additionally, factors such as production interruptions due to aging factory equipment, outdated technology, or production line upgrades; sharp fluctuations in market demand triggered by seasonal epidemics; and insufficient production incentives for manufacturers caused by the low prices of certain essential medicines also significantly impact drug supply.

To address these challenges, governments and pharmaceutical companies worldwide are taking measures to enhance the stability and resilience of drug supply chains. A key strategy for improving supply chain stability is to increase the sensitivity of monitoring and timely response by establishing multi-source information collection platforms and collaborative monitoring mechanisms, thereby achieving interconnectedness and sharing of information on active pharmaceutical ingredients (APIs) and finished formulations across registration, production, procurement, and pricing.

Among these, the application of synthetic biology helps address drug shortages by enabling rapid response to market demand, large-scale production of pharmaceutical ingredients through biological fermentation, and reduced costs, thereby improving the availability of active pharmaceutical ingredients (APIs).

Antheia is the leader in this field. Founded in 2015 and spun out of Stanford University’s Smolke Laboratory, Antheia was established on the premise that yeast can be programmed to efficiently produce complex pharmaceutical ingredients. The company is dedicated to leveraging synthetic biology to develop more effective solutions for the sustainable and responsible production of medicines, thereby promoting more equitable health outcomes worldwide.

Dr. Christina Smolke, Co-founder and CEO of Antheia, is a Professor of Bioengineering at Stanford University. She synthesized opioid compounds by assembling 23 different genes from plants, mammals, bacteria, and yeast, earning her a spot among Nature’s “Ten People Who Mattered in 2015.”

To date, Antheia has raised over $141 million from investors including Viking Global, Sherpalo Ventures, and Hillspire, the investment firm of billionaire Eric Schmidt. In 2021, Antheia completed its Series B financing round, raising $73 million to bring its first pharmaceutical compounds to market, expand its product pipeline, and scale up production for the global market.

Leveraging synthetic biology technologies, Antheia aims to produce key starting materials (KSMs) and active pharmaceutical ingredients (APIs) for biosynthetic essential medicines in a more efficient, flexible, and sustainable manner.

Key Starting Material (KSM) refers to the compound that introduces the first critical structural fragment of the final structure of the active pharmaceutical ingredient during the synthesis of an active pharmaceutical ingredient (API). KSM serves as the starting point for API synthesis and is typically a relatively complex organic molecule that is converted into the API through a series of chemical reactions.

Synthetic biology technologies can be employed to produce Key Starting Materials (KSMs) through gene editing and biofermentation, aiming for more efficient and sustainable production of these critical inputs. According to Antheia, 40% of KSMs and Active Pharmaceutical Ingredients (APIs) are currently derived from natural sources. Cultivating crops for pharmaceutical use is a slow, inefficient, and risk-laden process that renders the pharmaceutical supply chain vulnerable and frequently leads to shortages of essential and critical medicines.

To this end, Antheia has established a revolutionary alternative to traditional methods and built a full-chain production system focused on KSMs and APIs.

First, Antheia’s platform is capable of producing some of the most complex small-molecule drugs via fermentation. By employing whole-cell engineering approaches, the Antheia team has reconstructed biosynthetic pathways of unprecedented complexity and length in yeast cells, significantly expanding the range of compounds that can be produced through fermentation. Using these engineered yeast cells, Antheia can convert sugars into complex molecules.

Next is Antheia’s microbial factory engineering assembly line. By collecting genomic information from various organisms in nature, Antheia can apply advanced bioinformatics tools to search, analyze, and identify genes encoding enzymes that catalyze the production of valuable and complex natural products. Antheia then encodes yeast DNA with blueprints for producing complex, highly potent pharmaceutical small molecules. In this way, the company achieves its goal of designing molecular factory assembly lines within yeast, precisely controlling how enzymes work together to construct biosynthetic pathways.

Having engineered these microbial strains, Antheia is dedicated to optimizing fermentation and downstream processing. By leveraging high-throughput workflows, the company can perform small-scale quantitative performance characterization of tens of thousands of strain designs each month, while developing fermentation and downstream chemical processes to produce and purify target molecules.

However, for synthetic biology companies, scalable production remains the most critical bottleneck. Adapting R&D to industrial scale is Antheia’s ultimate goal. According to the company, while screening strains and developing processes, it simultaneously began defining its full-scale production capabilities and expanding to commercial scale. Although many strains perform well at the laboratory scale, transitioning these same processes to pilot scale (up to 500 liters) and ultimately to industrial scale (>100,000 liters) is highly complex, requiring deep integration across R&D, manufacturing, process engineering, supply chain, quality assurance, quality control, and regulatory affairs. Antheia’s processes, along with their multiple iterations, provide an optimal pathway for transitioning to pilot and full-scale production.

To pave a clear path for transitioning these simplified workflows into industrial-scale manufacturing, Antheia has developed advanced analytics and modeling tools to optimize, streamline, and systematize the discovery and design processes of its technology platform. Leveraging extensive internal datasets accumulated through its R&D processes, the company has significantly enhanced its biomanufacturing platform using data-driven approaches.

With such platform-based technical support, Antheia can optimize overall costs and production efficiency, significantly reduce production time, and achieve on-demand, rapid-response manufacturing.

Currently, Antheia’s product portfolio is fully aligned with the U.S. FDA requirements and the World Health Organization’s Model List of Essential Medicines, with its technology supporting efforts to improve global access to essential medicines. The company’s product lineup spans multiple therapeutic areas, including neurology, respiratory diseases, anti-infectives, and oncology.

After eight years of development, in August 2023, Antheia announced the completion of its first commercial-scale production.

Antheia’s first commercial-scale fermentation product is thebaine, a key ingredient in analgesic and addiction-treatment medications such as oxycodone, buprenorphine, naloxone, nalbuphine, oxymorphone, and etorphine. In the field of synthetic biology, thebaine can be biosynthesized using genetically engineered microorganisms such as yeast, offering an alternative to traditional extraction methods for its production.

According to news reports, Antheia utilizes highly engineered microorganisms—featuring 25–30 complex heterologous biosynthetic steps and more than 20 enzymes—to produce plant-derived active pharmaceutical ingredients (APIs), thereby enhancing the scale and efficiency of manufacturing such drugs. The company produced 116,000 liters of thebaine in approximately five days and achieved fermentation product concentrations at commercially viable levels, marking a significant commercial breakthrough for the company in the field of synthetic biology.

“Our first full-scale fermentation production marks a technical achievement in the scalable manufacturing of complex small-molecule drugs, as well as significant progress toward commercialization. With Antheia’s technology, customers can gain greater control and predictability over their drug production supply chains,” said Dr. Christina Smolke, CEO and Co-Founder of Antheia. “It is truly exciting to see our commercial advancements align with our mission to transform the pharmaceutical supply chain and enable more equitable access to medicines.”

According to the R&D objectives published on the company’s official website, in addition to thebaine, their products include oripavine and scopolamine, all of which serve as key starting materials (KSMs) or active pharmaceutical ingredients (APIs) for the production of small-molecule drugs. Their product pipeline encompasses analgesic and addiction-treatment medications such as codeine, hydrocodone, and naloxone derived from oripavine, as well as antiemetic and antispasmodic drugs derived from scopolamine.

Currently, Antheia’s pipeline covers therapeutic areas including neurology, respiratory diseases, anti-infectives, oncology, gastroenterology, endocrinology, and hematology. Looking ahead, having achieved significant commercialization milestones, Antheia will launch its first products to the market within the next two years, leveraging synthetic biology to fulfill its promise of transforming supply chain challenges in the pharmaceutical industry.